Growth Metrics

Regenxbio (RGNX) Total Current Liabilities (2016 - 2025)

Regenxbio has reported Total Current Liabilities over the past 12 years, most recently at $118.1 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $118.1 million for Q4 2025, up 14.44% from a year ago — trailing twelve months through Dec 2025 was $118.1 million (up 14.44% YoY), and the annual figure for FY2025 was $118.1 million, up 14.44%.
  • Total Current Liabilities for Q4 2025 was $118.1 million at Regenxbio, down from $124.6 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for RGNX hit a ceiling of $130.5 million in Q4 2021 and a floor of $84.0 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $116.2 million (2022), compared with a mean of $113.6 million.
  • Biggest five-year swings in Total Current Liabilities: soared 164.12% in 2021 and later dropped 20.79% in 2024.
  • Regenxbio's Total Current Liabilities stood at $130.5 million in 2021, then dropped by 0.03% to $130.4 million in 2022, then fell by 0.12% to $130.3 million in 2023, then decreased by 20.79% to $103.2 million in 2024, then rose by 14.44% to $118.1 million in 2025.
  • The last three reported values for Total Current Liabilities were $118.1 million (Q4 2025), $124.6 million (Q3 2025), and $119.5 million (Q2 2025) per Business Quant data.